ReviewSTAR protocols2026
A decision-driven framework for the mass spectrometry analysis of previously uncharacterized protein modifications.
Review in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of unknown protein modifications remains challenging when the modification chemistry or site is not defined in advance. Conventional workflows often rely on predefined modification lists or enrichment strategies that assume prior knowledge of modification type and may therefore bias discovery toward annotated post-translational modifications (PTMs). This primer outlines a decision-driven analytical framework for investigating previously uncharacterized modifications using bottom-up (liquid chromatography-tandem mass spectrometry) LC-MS/MS that emphasizes chemistry-informed hypothesis generation, iterative refinement of candidate modification search space, integration of experimental controls, and targeted data interpretation. Rather than presenting a single prescriptive workflow, the guide highlights key decision points in experimental design, acquisition strategy, and database search configuration that influence confident identification and residue-level localization. The framework is broadly applicable to drug-induced covalent adducts, chemically introduced modifications, as well as endogenous modifications arising across diverse experimental and biological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.